Publication
Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial.
Journal Paper/Review - Oct 27, 2023
Urwyler Pascal, Leimbacher Marina, Charitos Panteleimon, Moser Stephan, Fehrman-Ekholm Ingela, Trendelenburg Marten, Thoma Reto, Sumer Johannes, Camacho-Ortiz Adrián, Bacci Marcelo R, Huber Lars Chistian, Stüssi-Helbling Melina, Albrich Werner, Sendi Parham, Osthoff Michael
Units
PubMed
Doi
Contact
Citation
Urwyler P, Leimbacher M, Charitos P, Moser S, Fehrman-Ekholm I, Trendelenburg M, Thoma R, Sumer J, Camacho-Ortiz A, Bacci M, Huber L, Stüssi-Helbling M, Albrich W, Sendi P, Osthoff M. Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial. Front Immunol 2023; 14:1255292.
Type
Journal Paper/Review (English)
Journal
Front Immunol 2023; 14
Publication Date
Oct 27, 2023
Issn Electronic
1664-3224
Pages
1255292
Brief description/objective
Conestat alfa (ConA), a recombinant human C1 inhibitor, may prevent thromboinflammation.